Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUXEDO-3: Patritumab deruxtecan in brain and leptomeningeal metastases
2023-503251-10-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in breast cancer, non-small cell lung cancer (NSCLC), Nonhematologic neoplasms and 2 more, sponsored by MEDSIR. Primary endpoints: Intracranial objective response rate (ORR-IC) for cohorts 1 and 2 and 3-month overall survival rate for cohort 3. Started Oct 2023; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)Nonhematologic neoplasmsbrain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on 2023-503251-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503251-10-00.